Tumor

As BIO 2021 Approaches, Taiwan's DCB Reveals Competitive Bio-Innovations to Watch Out for

Retrieved on: 
Monday, June 14, 2021
Tumor, Tumor microenvironment

What's more, DCB holds the 2021 Taiwan Biotech Forum before the BIO 2021 under the topic of "Preparing for the Next Pandemic: Ready, Set and Go!

Key Points: 
  • What's more, DCB holds the 2021 Taiwan Biotech Forum before the BIO 2021 under the topic of "Preparing for the Next Pandemic: Ready, Set and Go!
  • Dr. Chung-Hsiun Wu, President of DCB points out some of the highlights.
  • DCB now is expecting to tackle issues with the tumor microenvironment and leads to a stronger cytotoxic effect on solid tumors.
  • The technology would be one of the main focuses of Bio Digital 2021, surely attracting CDMO and biopharma firms.

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Retrieved on: 
Thursday, June 3, 2021
Tumor, Tumor microenvironment, Cancer

HOUSTON, June 03, 2021 (GLOBE NEWSWIRE) -- Stellanova Therapeutics, Inc. (Stellanova), a biotechnology company advancing cancer therapies targeting the tumor microenvironment, today announced the closing of a $15.5 million Series A financing led by Sporos Bioventures, LLC.

Key Points: 
  • HOUSTON, June 03, 2021 (GLOBE NEWSWIRE) -- Stellanova Therapeutics, Inc. (Stellanova), a biotechnology company advancing cancer therapies targeting the tumor microenvironment, today announced the closing of a $15.5 million Series A financing led by Sporos Bioventures, LLC.
  • Stellanova is focused on targeting the many pro-tumorigenic effects enabled by the activity of carcinoma-associated fibroblasts (known as CAFs) in the tumor microenvironment.
  • Harold Levy, Stellanova and Sporos founder and board member, added, We are thrilled to bring Stellanova into the Sporos group of companies.
  • Stellanova means new star, and it is clear the Stellanova team embraces this namesake with their entirely new approach to treating cancer.

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Retrieved on: 
Tuesday, June 1, 2021
Tumor, Cancer pathology, Oncology, Tumor microenvironment, Metástasis, Branches of biology

This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer.

Key Points: 
  • This new integrin program, in addition to the existing endocannabinoid system program, strengthens and diversifies Corbus immunology pipeline for inflammatory, fibrotic, and metabolic diseases, and cancer.
  • TGF plays a key role in fibrosis and also promotes cancer growth and metastasis via its effects in the tumor microenvironment (TME).
  • The integrins v6 and v8 are expressed by cancer cells, and v6 is also expressed on epithelial cells in fibrotic diseases.
  • Corbus believes targeting both integrins at once is a rational approach to treating fibrotic diseases and carcinomas.

NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Medical specialties, Branches of biology, Clinical medicine, Immunology, Immune system, T cell, Tumor, Tumor microenvironment, Interleukins

\xe2\x80\x9cLAIR-1 expression on immune cells in the TME inhibits T cell responses, through binding to collagen therefore leading to tumor growth.

Key Points: 
  • \xe2\x80\x9cLAIR-1 expression on immune cells in the TME inhibits T cell responses, through binding to collagen therefore leading to tumor growth.
  • This leads to restoration of immune function as evidenced by increased production of several cytokines, and anti-tumor responses in preclinical models.
  • Because NC410 binds to collagen rich areas, it also induces alterations in the ECM to promote immune cell infiltration and function in the TME.
  • These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof.

Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., M.B.A.

Retrieved on: 
Thursday, May 13, 2021
Medicine, Clinical medicine, Medical specialties, Immunology, Tumor, Cancer treatments, Tumor microenvironment, Cytokine, HER2/neu

In addition, her visionary leadership will contribute to our strategic focus of building out our pipeline of masked T cell engagers and cytokines.\xe2\x80\x9d\nDr.

Key Points: 
  • In addition, her visionary leadership will contribute to our strategic focus of building out our pipeline of masked T cell engagers and cytokines.\xe2\x80\x9d\nDr.
  • Kennedy added, \xe2\x80\x9cI am delighted to join Amunix\xe2\x80\x99s board and am excited about the potential of its proprietary Pro-XTEN technology to harness the untapped potential of T-cell engagers and cytokines.
  • Amunix\xe2\x80\x99s Pro-XTEN technology leverages the intrinsically high protease activity in the tumor microenvironment to preferentially unmask and activate our drugs in the tumor microenvironment.
  • Amunix\xe2\x80\x99s most advanced product candidate, AMX-818, is a masked HER2-targeted TCE for the treatment of HER2-expressing solid tumors, which is currently in IND-enabling studies.

Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings

Retrieved on: 
Monday, May 10, 2021
Biotechnology, Medical devices, Health, Pharmaceutical, Oncology, Branches of biology, Clinical medicine, Medicine, Tumor, DNA replication, Ribonucleoproteins, Senescence, Telomerase, Immunotherapy, Tumor microenvironment, Cancer vaccine, Immune system

The full poster presentation from the ASCO Annual Meeting will be available on the Ultimovacs website on 4 June 2021.\nDetails of the investor events:\nPresenter: Carlos de Sousa, CEO.

Key Points: 
  • The full poster presentation from the ASCO Annual Meeting will be available on the Ultimovacs website on 4 June 2021.\nDetails of the investor events:\nPresenter: Carlos de Sousa, CEO.
  • Ultimovacs\xe2\x80\x99 lead universal cancer vaccine candidate UV1 leverages the high prevalence of the human telomerase (hTERT) to be effective across the dynamic stages of the tumor\xe2\x80\x99s growth and its microenvironment.
  • By directing the immune system to hTERT antigens that are present in over 80% of all cancers, UV1 drives CD4 helper T cells to the tumor with the goal of activating an immune system cascade to increase anti-tumor responses.
  • Ultimovacs\xe2\x80\x99 strategy is to clinically demonstrate UV1\xe2\x80\x99s impact in many cancer types and in combination with other immunotherapies.

CARISMA Therapeutics to Present Data at The American Society of Gene & Cell Therapy 24th Annual Meeting

Retrieved on: 
Wednesday, April 28, 2021
Clinical medicine, Medicine, Medical specialties, Tumor, Tumor microenvironment, Immunotherapy, Oncology, Immune system, Cancer immunotherapy, Immune checkpoint

b'PHILADELPHIA, April 28, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced findings from two studies accepted for virtual presentation at The American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting on Tuesday, May 11 Friday, May 14.

Key Points: 
  • b'PHILADELPHIA, April 28, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced findings from two studies accepted for virtual presentation at The American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting on Tuesday, May 11 Friday, May 14.
  • The findings demonstrate that CAR-M therapy showed significant tumor control, increased overall survival, remodeled tumor microenvironment, and protected mice from antigen negative tumor recurrence.
  • The results also exhibit that CAR-M synergize with T cell checkpoint inhibitors against PD1 resistant solid tumors.
  • CARISMA Therapeutics is headquartered in Philadelphia, PA.\n'

Kanazawa University research: Tracing tumors: targeting and imaging cancer cells

Retrieved on: 
Tuesday, April 27, 2021
Carcinogenesis, Health, Immune system, Cancer cell, Cancer, Breast cancer, Clinical medicine, Medicine, Tumor, Oncology, Metastatic breast cancer, Somatostatin receptor 2

For example, platelet-derived growth factor receptor (PDGFR) which is often found on breast and colon cancer cells has been used to design probes that can attach to it and facilitate imaging of these cells.

Key Points: 
  • For example, platelet-derived growth factor receptor (PDGFR) which is often found on breast and colon cancer cells has been used to design probes that can attach to it and facilitate imaging of these cells.
  • All such tracers designed to date have shown low accumulation within tumor tissues making it hard to visualize the cancer accurately.
  • Peptides are miniature proteins that quickly hustle into different organs in the body without attracting much attention from the immune system.
  • These two tracers also showed high uptake when incubated with cancer cells.

Kanazawa University research: Tracing tumors: targeting and imaging cancer cells

Retrieved on: 
Tuesday, April 27, 2021
Carcinogenesis, Health, Immune system, Cancer cell, Cancer, Breast cancer, Clinical medicine, Medicine, Tumor, Oncology, Metastatic breast cancer, Somatostatin receptor 2

For example, platelet-derived growth factor receptor (PDGFR) which is often found on breast and colon cancer cells has been used to design probes that can attach to it and facilitate imaging of these cells.

Key Points: 
  • For example, platelet-derived growth factor receptor (PDGFR) which is often found on breast and colon cancer cells has been used to design probes that can attach to it and facilitate imaging of these cells.
  • All such tracers designed to date have shown low accumulation within tumor tissues making it hard to visualize the cancer accurately.
  • Peptides are miniature proteins that quickly hustle into different organs in the body without attracting much attention from the immune system.
  • These two tracers also showed high uptake when incubated with cancer cells.

PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases

Retrieved on: 
Wednesday, April 14, 2021
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Clinical medicine, Medicine, Immune system, Branches of biology, Tumor, Tumor microenvironment, Chimeric antigen receptor T cell, PsiOxus, T-SIGn®, bluebird bio, Inc.

\xe2\x80\x9cThese data validate the potential of our T-SIGn platform to reprogram the tumor microenvironment such that CAR-T cells are recruited, activated and sustained within solid tumors to yield efficacy.

Key Points: 
  • \xe2\x80\x9cThese data validate the potential of our T-SIGn platform to reprogram the tumor microenvironment such that CAR-T cells are recruited, activated and sustained within solid tumors to yield efficacy.
  • Our validated T-SIGn\xc2\xae vector platform can deliver multiple transgene payloads that reengineer both primary and metastatic tumors.
  • We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
  • \xe2\x80\x8b\nTumor-Specific Immuno-Gene Therapy (T-SIGn) is a broad platform for tumor re-engineering by delivering combinations of transgenes encoding immunotherapeutic proteins.